Vigani A, Pensa F, Vaira F, Bancalari L, Cordani S, Maggiani R, Canessa P, Pronzato P
Department of Medical Oncology, S. Andrea Hospital, La Spezia, Italy.
Anticancer Res. 2000 Sep-Oct;20(5C):4015-8.
16 patients with advanced small cell lung cancer were treated with a combination of cyclophosphamide (1000 mg/m2 day 1), epidoxorubicin (60 mg/m2 day 1) and vincristine (1.4 mg/m2 day 1) every 14 days for six cycles followed by a combination of cisplatin (40 mg/m2 days 1 & 2) and etoposide (100 mg/m2 days 1-3) every 14 days for four cycles. Shortening of intervals was obtained with the prophylactic employment of granulocyte colony-stimulating factor (filgrastim, 300 mcg subcutaneously from day 5 to dsy 10). In 11 patients ratio between actually delivered dose intensity and planned dose intensity of > 80% was obtained. Toxicity was acceptable and no life-threatening toxicities were observed. An objective response (partial or complete) was observed in 11 patients. The new regimen, incorporating the concepts of dose-intensification and sequential administration of regimens, is feasible and may be considered for further studies.
16例晚期小细胞肺癌患者接受如下治疗：每14天给予环磷酰胺（1000mg/m²，第1天）、表柔比星（60mg/m²，第1天）和长春新碱（1.4mg/m²，第1天）联合用药，共六个周期；随后每14天给予顺铂（40mg/m²，第1天和第2天）和依托泊苷（100mg/m²，第1 - 3天）联合用药，共四个周期。通过预防性使用粒细胞集落刺激因子（非格司亭，从第5天至第10天皮下注射300μg）实现了给药间隔的缩短。11例患者实际给药剂量强度与计划剂量强度之比大于80%。毒性可接受，未观察到危及生命的毒性反应。11例患者观察到客观缓解（部分或完全缓解）。新方案结合了剂量强化和序贯给药的概念，是可行的，可考虑进一步研究。
